Showing 19,581 - 19,600 results of 74,121 for search '(( 50 ((nn decrease) OR (a decrease)) ) OR ( 5 ((we decrease) OR (mean decrease)) ))', query time: 0.81s Refine Results
  1. 19581

    DataSheet1_OsPDIL1-5: dual role in promoting growth and development while modulating drought stress tolerance in rice (Oryza sativa L.).docx by Jilin Chen (19847928)

    Published 2024
    “…Through map-based cloning, we determined that the protein disulfide isomerase-like (PDIL) gene OsPDIL1-5 is the GDDT gene. …”
  2. 19582

    Conformational changes measured by fluorescence correlation spectrometry (FCS). by Sabina Eigenbrod (187226)

    Published 2017
    “…Addition of metal ions like copper (Cu<sup>2+</sup>) and manganese (Mn<sup>2+</sup>) as well as depletion of divalent metal ions with EDTA in the presence of 0.02% SDS had a much stronger impact on the aggregation of wt-rPrP than on TetraH>G-rPrP and H95G-rPrP. Data are shown as mean values of last five meanders ± SEM of four to six independent experiments with four replicates each.…”
  3. 19583
  4. 19584

    Table 5_The burden and etiologies of diarrhea in Asia and its countries from 1990 to 2021 and the forecast to 2040: analyses informed by the global burden of disease study 2021.doc... by Shan Liu (193759)

    Published 2025
    “…</p>Results<p>Overall burden showed that the ASRs in Asia decreased from 1990 to 2021, with EAPCs of −0.40, −0.55, −5.70, and −5.47, respectively. …”
  5. 19585

    Table_1_v1_Elevated Admission Cardiac Troponin I Predicts Adverse Outcomes of Acute Type B Aortic Dissection after Endovascular Treatment.docx by Kaiwen Zhao (12804869)

    Published 2022
    “…Background<p>There is a lack of evidence about the predictive role of serum cardiac troponin I (cTnI) on the long-term adverse outcomes of acute type B aortic dissection (aTBAD) patients after thoracic endovascular aortic repair (TEVAR). In this study, we identified whether cTnI was an independent risk factor of 5-year adverse outcomes for aTBAD patients after TEVAR.…”
  6. 19586

    Image_3_DNMT3A R882 Mutations Confer Unique Clinicopathologic Features in MDS Including a High Risk of AML Transformation.tif by Majd Jawad (12157533)

    Published 2022
    “…By data mining with publicly accessible cancer genomics databases and a clinical genomic database from a tertiary medical institution, DNMT3A R882 mutations were found to be enriched in AML (53% of all DNMT3A mutations) but decreased in frequency in clonal hematopoiesis of indeterminate potential (CHIP) (10.6%) or other myeloid neoplasms including MDS (27%) (p<.001). …”
  7. 19587

    Image_1_DNMT3A R882 Mutations Confer Unique Clinicopathologic Features in MDS Including a High Risk of AML Transformation.tif by Majd Jawad (12157533)

    Published 2022
    “…By data mining with publicly accessible cancer genomics databases and a clinical genomic database from a tertiary medical institution, DNMT3A R882 mutations were found to be enriched in AML (53% of all DNMT3A mutations) but decreased in frequency in clonal hematopoiesis of indeterminate potential (CHIP) (10.6%) or other myeloid neoplasms including MDS (27%) (p<.001). …”
  8. 19588

    Image_2_DNMT3A R882 Mutations Confer Unique Clinicopathologic Features in MDS Including a High Risk of AML Transformation.tif by Majd Jawad (12157533)

    Published 2022
    “…By data mining with publicly accessible cancer genomics databases and a clinical genomic database from a tertiary medical institution, DNMT3A R882 mutations were found to be enriched in AML (53% of all DNMT3A mutations) but decreased in frequency in clonal hematopoiesis of indeterminate potential (CHIP) (10.6%) or other myeloid neoplasms including MDS (27%) (p<.001). …”
  9. 19589

    Table_2_DNMT3A R882 Mutations Confer Unique Clinicopathologic Features in MDS Including a High Risk of AML Transformation.docx by Majd Jawad (12157533)

    Published 2022
    “…By data mining with publicly accessible cancer genomics databases and a clinical genomic database from a tertiary medical institution, DNMT3A R882 mutations were found to be enriched in AML (53% of all DNMT3A mutations) but decreased in frequency in clonal hematopoiesis of indeterminate potential (CHIP) (10.6%) or other myeloid neoplasms including MDS (27%) (p<.001). …”
  10. 19590

    Table_1_DNMT3A R882 Mutations Confer Unique Clinicopathologic Features in MDS Including a High Risk of AML Transformation.docx by Majd Jawad (12157533)

    Published 2022
    “…By data mining with publicly accessible cancer genomics databases and a clinical genomic database from a tertiary medical institution, DNMT3A R882 mutations were found to be enriched in AML (53% of all DNMT3A mutations) but decreased in frequency in clonal hematopoiesis of indeterminate potential (CHIP) (10.6%) or other myeloid neoplasms including MDS (27%) (p<.001). …”
  11. 19591
  12. 19592
  13. 19593

    Table_2_α-Ketoglutarate stimulates cell growth through the improvement of glucose and glutamine metabolism in C2C12 cell culture.DOCX by Bingquan Yang (6389006)

    Published 2023
    “…</p>Results<p>The control cells showed a CFE at 50%, a typical cell growth curve in the first 5 days with a mean SGR at 0.86/day, and a mean cell count doubling time at 19.4 h. …”
  14. 19594

    Table_6_α-Ketoglutarate stimulates cell growth through the improvement of glucose and glutamine metabolism in C2C12 cell culture.DOCX by Bingquan Yang (6389006)

    Published 2023
    “…</p>Results<p>The control cells showed a CFE at 50%, a typical cell growth curve in the first 5 days with a mean SGR at 0.86/day, and a mean cell count doubling time at 19.4 h. …”
  15. 19595

    Table_3_α-Ketoglutarate stimulates cell growth through the improvement of glucose and glutamine metabolism in C2C12 cell culture.DOCX by Bingquan Yang (6389006)

    Published 2023
    “…</p>Results<p>The control cells showed a CFE at 50%, a typical cell growth curve in the first 5 days with a mean SGR at 0.86/day, and a mean cell count doubling time at 19.4 h. …”
  16. 19596

    Table_8_α-Ketoglutarate stimulates cell growth through the improvement of glucose and glutamine metabolism in C2C12 cell culture.DOCX by Bingquan Yang (6389006)

    Published 2023
    “…</p>Results<p>The control cells showed a CFE at 50%, a typical cell growth curve in the first 5 days with a mean SGR at 0.86/day, and a mean cell count doubling time at 19.4 h. …”
  17. 19597

    Table_7_α-Ketoglutarate stimulates cell growth through the improvement of glucose and glutamine metabolism in C2C12 cell culture.DOCX by Bingquan Yang (6389006)

    Published 2023
    “…</p>Results<p>The control cells showed a CFE at 50%, a typical cell growth curve in the first 5 days with a mean SGR at 0.86/day, and a mean cell count doubling time at 19.4 h. …”
  18. 19598

    Table_4_α-Ketoglutarate stimulates cell growth through the improvement of glucose and glutamine metabolism in C2C12 cell culture.DOCX by Bingquan Yang (6389006)

    Published 2023
    “…</p>Results<p>The control cells showed a CFE at 50%, a typical cell growth curve in the first 5 days with a mean SGR at 0.86/day, and a mean cell count doubling time at 19.4 h. …”
  19. 19599

    Table_9_α-Ketoglutarate stimulates cell growth through the improvement of glucose and glutamine metabolism in C2C12 cell culture.DOCX by Bingquan Yang (6389006)

    Published 2023
    “…</p>Results<p>The control cells showed a CFE at 50%, a typical cell growth curve in the first 5 days with a mean SGR at 0.86/day, and a mean cell count doubling time at 19.4 h. …”
  20. 19600

    Table_1_α-Ketoglutarate stimulates cell growth through the improvement of glucose and glutamine metabolism in C2C12 cell culture.DOCX by Bingquan Yang (6389006)

    Published 2023
    “…</p>Results<p>The control cells showed a CFE at 50%, a typical cell growth curve in the first 5 days with a mean SGR at 0.86/day, and a mean cell count doubling time at 19.4 h. …”